Please login to the form below

Not currently logged in
Email:
Password:

Genzyme wins Scottish approval for Renvela

Genzyme UK can supply Renvela within NHS Scotland after securing Scottish Medicine Consortium approval

Genzyme UK, a subsidiary of sanofi-aventis group, has received approval from the Scottish Medicine Consortium (SMC) to use Renvela within NHS Scotland as a treatment for hyperphosphataemia in adult patients with chronic kidney disease (CKD).

Renvela is a medication for the control of serum phosphorous in patients with CKD. Kidney failure causes levels of phosphate to rise in the blood, as the patient's kidneys are not able to excrete excess phosphate into the urine. Phosphorous build up is also associated with calcification of certain vessels.

Dr Alan Jardine, professor of renal medicine and head of the undergraduate medical school at University of Glasgow, said: "The availability of Renvela offers an efficacious addition to this class of agent, where existing therapies may have limited efficacy and poor patient compliance."

13th April 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics